STOXX 600Health Care· Denmark

GMAB

Dependent

Genmab

$1,804.00

+0.78%

Open $1,778.50·Prev $1,790.00

as of 17 Apr

DEPENDENT

Power Core

Genmab's moat is genuine but narrow: its proprietary antibody engineering platforms, primarily DuoBody (bispecific antibodies) and HexaBody (hexameric antibody formats), produce molecules that larger pharmaceutical companies license because internal discovery cannot replicate the platform economics.

Published19 Apr 2026

UniverseSTOXX 600

SectorHealth Care

↑

Direction of Movement

lateral

ROC 200

+39.4%